Abstract:The coronavirus papain-like protease (PLpro) is crucial for viral replicase polyprotein processing. Additionally, PLpro can subvert host defense mechanisms by its deubiquitinating (DUB) and deISGylating activities. To elucidate the role of these activities during SARS-CoV-2 infection, we introduced mutations that disrupt binding of PLpro to ubiquitin or ISG15. We identified several mutations that strongly reduced DUB activity of PLpro, without affecting viral polyprotein processing. In contrast, mutations that abrogated deISGylating activity also hampered viral polyprotein processing and when introduced into the virus these mutants were not viable. SARS-CoV-2 mutants exhibiting reduced DUB activity elicited a stronger interferon response in human lung cells. In a mouse model of severe disease, disruption of PLpro DUB activity did not affect lethality, virus replication, or innate immune responses in the lungs. This suggests that the DUB activity of SARS-CoV-2 PLpro is dispensable for virus replication and does not affect innate immune responses in vivo . Interestingly, the DUB mutant of SARS-CoV replicated to slightly lower titers in mice and elicited a diminished immune response early in infection, although lethality was unaffected. We previously showed that a MERS-CoV mutant deficient in DUB and deISGylating activity was strongly attenuated in mice. Here, we demonstrate that the role of PLpro DUB activity during infection can vary considerably between highly pathogenic coronaviruses. Therefore, careful considerations should be taken when developing pan-coronavirus antiviral strategies targeting PLpro. The COVID-19 pandemic highlighted the need for pan-coronavirus targeting antivirals and vaccines. One of the potential targets is the viral papain-like protease (PLpro). PLpro is required for processing of the viral replicase polyprotein, thus enabling virus replication, but it also contributes to immune evasion by its deubiquitinating and deISGylating activities. Here we show that the deubiquitinating activity of SARS-CoV-2 PLpro does not influence virus replication, innate immune responses or lethality in mice. For SARS-CoV, we found that a mutant virus lacking deubiquitinating activity replicated to slightly lower titers and elicited a diminished immune response. This is in strong contrast to our previous findings for MERS-CoV, where removal of the deubiquitinating and deISGylating activities of PLpro strongly attenuated the virus in mice, completely alleviating lethality, and rendered it a promising live-attenuated vaccine candidate. This study uncovers important differences between highly pathogenic coronaviruses in the differential roles of PLpro during infection. These mechanistic insights provide valuable information for the development of pan-coronavirus targeting antivirals and vaccines.

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‐2 papain-like protease

SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design

Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro

Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules

Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

Drug Repurposing for the SARS‐CoV‐2 Papain‐Like Protease

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity

The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING

Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships

Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies

SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

Investigating Derivatives of Tanshinone IIA Sulfonate Sodium and Chloroxine for Their Inhibition Activities Against the SARS-CoV-2 Papain-like Protease

Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo

Crystal structure of SARS-CoV-2 papain-like protease